IBAB Ion Beam Applications SA

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida 

          

Louvain-La-Neuve, Belgium, October 24, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that its proton therapy contract with Advocate Radiation Oncology, via its affiliate Southwest Florida Proton, has been finalized. IBA will start to recognize revenue from the contract in 2021.

The finalization of the contract follows the announcement earlier in the year that IBA had been selected by Advocate Radiation Oncology for its new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County. The contract involves the delivery of IBA’s Proteus®ONE* solution including Pencil Beam Scanning (PBS), Cone Beam CT (CBCT), Philips Ambient and a fully integrated quality assurance (QA) hardware and software package from IBA Dosimetry America, Inc. Advocate Radiation Oncology expects to start treating patients by 2023.

The typical end-user price for a Proteus®ONE system with a 10-year maintenance contract ranges between 40 and 50 million US dollars.

Olivier Legrain, Chief Executive Officer of IBA, commented: “The finalization of this contract highlights the growing momentum of proton therapy in the US. As we continue to reinforce our position in the region, we are hugely excited about the future opportunity there. We look forward to attending the ASTRO meeting this weekend and engaging with further potential partners.”

Arie Dosoretz, CEO of Advocate Radiation Oncology, said: “We are firmly committed to providing the cancer patients of Southwest Florida with every radiation option they need and are excited for the next steps of this critical project. IBA delivers the most innovative proton technology in the world, and our patients deserve nothing less.”

*Proteus®ONE is a brand name of Proteus 235

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About Advocate Radiation Oncology

Advocate Radiation Oncology is a locally owned practice with convenient locations in South Florida. The practice’s mission is to provide compassionate health care expertise to cancer patients. Advocate Radiation Oncology is directed by a team of world-class, board-certified radiation oncologists,

For more information, please visit . 

CONTACTS

Soumya Chandramouli

Chief Financial Officer



Olivier Lechien

Corporate Communication Director



Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
24/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

 PRESS RELEASE

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expan...

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...

 PRESS RELEASE

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre...

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 16th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 16 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch